> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# iRhythm Targets $890 Million–$895 Million In Sales As Zio Demand Exceeds Its Expectations
- URL: https://www.bullished.co/irhythm-targets-890-million-895-million-in-sales-as-zio-demand-exceeds-its-expectations-db263ef5/
- Published: 2026-11-06T13:57:28.000Z
- Updated: 2026-11-06T13:57:28.000Z
- Description: The higher outlook includes VitalConnect revenue, while litigation charges widened the quarterly loss.
- Author: Matteo Parrino
- Tags: SEC Filings, IRTC, Industry: Healthcare

[iRhythm Holdings](https://www.bullished.co/tag/irtc/), which helps doctors diagnose irregular heart rhythms through wearable cardiac monitors, raised its 2026 sales outlook to [$890 million–$895 million](https://www.sec.gov/Archives/edgar/data/0001388658/000138865826000093/irtc-20261105.htm?ref=bullished.co) Thursday, with Zio Monitor demand beating management’s expectations. The earnings release accompanying its SEC filing also raised the adjusted earnings margin forecast to 15.5%–16.0%, including the newly bought VitalConnect business.

## Zio Volumes Lift Sales And Margins

Third-quarter sales totaled [$221.6 million](https://www.sec.gov/Archives/edgar/data/0001388658/000138865826000093/irtcq32026ex991pressrelease.htm?ref=bullished.co), rising 14.9% from $192.9 million a year earlier. iRhythm credited customer volumes and newer sales channels, with growth across cardiology, primary care and international markets.

“Demand for Zio Monitor remains robust, [exceeding our expectations](https://www.sec.gov/Archives/edgar/data/0001388658/000138865826000093/irtcq32026ex991pressrelease.htm?ref=bullished.co) in the quarter, driven by volume growth across care settings and channels,” said Quentin Blackford, iRhythm’s president and chief executive officer.

Gross profit increased 20.0% to $164.5 million from $137.1 million. More Zio services and approximately $3.1 million of one-time tariff refunds helped; gross margin reached 74.2%, improving 3.10 percentage points as efficiencies and product mix also contributed.

Adjusted earnings before interest, taxes, depreciation and amortization reached $51.2 million, a $29.6 million improvement from the year-earlier quarter. The corresponding margin was 23.1%.

## Litigation Separates Loss From Adjusted Profit

Standard-accounting results went the other way. The quarterly net loss grew to $29.9 million, or $0.90 per diluted share, against $5.2 million, or $0.16 per share, a year earlier. Operating expenses reached $197.0 million versus $145.6 million, including $49.788 million in litigation settlement charges.

Those charges covered Baxter patent litigation and securities class-action settlements, net of expected insurance recoveries. The adjusted results excluded them, along with costs for business changes, intellectual-property litigation, impairments and the cybersecurity incident, among other adjustments.

Adjusted net income was $27.8 million, or $0.82 per diluted share, compared with a $2.0 million adjusted loss, or $0.06 per share. Adjusted operating expenses fell to $138.6 million from $141.4 million; management attributed the earnings improvement to sales growth and efficiency initiatives.

Cash generation also lagged the adjusted earnings result. Quarterly operating cash flow was $4.438 million versus $34.883 million a year earlier and included $50.0 million of Baxter settlement payments. After equipment and property purchases, free cash flow was negative $11.545 million, compared with positive $20.052 million.

## VitalConnect Broadens The Monitoring Business

iRhythm [completed its purchase](https://www.sec.gov/Archives/edgar/data/0001388658/000138865826000093/irtcq32026ex991pressrelease.htm?ref=bullished.co) of VitalConnect on October 5, adding an FDA-cleared mobile cardiac monitoring device. Its annual outlook includes approximately $16 million of expected VitalConnect sales between closing and year-end.

The existing Zio service combines a wireless patch that records heart signals for up to 14 days with cloud software. Trained technicians review reports before physicians receive them; customers include doctor practices and health systems, mainly in the United States, with a commercial presence in the United Kingdom, selected European countries and Japan.

iRhythm also submitted FDA applications to expand Zio Monitor use to children. The company said three published real-world studies covering more than 1.7 million patients supported its monitoring products, including improved Zio Monitor performance and diagnostic yield compared with Zio XT.

To support growth, iRhythm closed a $300 million secured revolving credit facility Tuesday. Unrestricted cash, cash equivalents and marketable securities stood at $560.7 million on September 30.

The year-end targets now include VitalConnect: management expects sales of $890 million–$895 million and an adjusted earnings-before-interest, taxes, depreciation-and-amortization margin of 15.5%–16.0%.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — iRhythm Holdings, Inc. (IRTC)](https://www.sec.gov/Archives/edgar/data/0001388658/000138865826000093/irtc-20261105.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit irtcq32026ex991pressrelease.htm — iRhythm Holdings, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001388658/000138865826000093/irtcq32026ex991pressrelease.htm?ref=bullished.co) — SEC EDGAR
- [IRhythm plans Zio MCT FDA filing in 2027 while raising 2026 revenue outlook to $890M-$895M (NASDAQ:IRTC)](https://seekingalpha.com/news/4667753-irhythm-plans-zio-mct-fda-filing-in-2027-while-raising-2026-revenue-outlook-to-890m-895m?ref=bullished.co) — seekingalpha.com
- [iRhythm (IRTC) Q3 2026 Earnings Call Transcript - The Globe and Mail](https://www.theglobeandmail.com/investing/markets/markets-news/Motley%20Fool/8691982/irhythm-irtc-q3-2026-earnings-call-transcript/?ref=bullished.co) — theglobeandmail.com
- [iRhythm Holdings Announces Third Quarter 2026 Financial](https://www.globenewswire.com/news-release/2026/11/05/3397028/0/en/irhythm-holdings-announces-third-quarter-2026-financial-results.html?ref=bullished.co) — globenewswire.com

### More on iRhythm Holdings

- [iRhythm CEO Says Hospitals Are Deferring Zio AT Onboarding Until VitalConnect Is Folded In](https://www.bullished.co/irhythm-ceo-says-hospitals-are-deferring-zio-at-onboarding-until-vitalconnect-is-folded-in-f030ee80/)
- [iRhythm Closes VitalConnect Purchase With $237.5 Million Cash And Up To 423,334 Shares](https://www.bullished.co/irhythm-closes-vitalconnect-purchase-with-237-5-million-cash-and-up-to-423-334-shares-04a4e7da/)

[All iRhythm Holdings (IRTC) coverage →](https://www.bullished.co/tag/irtc/)